UK markets closed

Aclaris Therapeutics, Inc. (0H8T.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
1.1850+0.0300 (+2.60%)
At close: 05:22PM BST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.23
52-week change 3-84.25%
S&P500 52-week change 322.36%
52-week high 310.8700
52-week low 30.6052
50-day moving average 31.2025
200-day moving average 34.3061

Share statistics

Avg vol (3-month) 312.28k
Avg vol (10-day) 314.01k
Shares outstanding 540.94M
Implied shares outstanding 6N/A
Float 850.49M
% held by insiders 12.48%
% held by institutions 195.25%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -283.15%
Operating margin (ttm)-134.99%

Management effectiveness

Return on assets (ttm)-32.53%
Return on equity (ttm)-49.88%

Income statement

Revenue (ttm)31.25M
Revenue per share (ttm)0.45
Quarterly revenue growth (yoy)126.60%
Gross profit (ttm)N/A
EBITDA -117.56M
Net income avi to common (ttm)-88.48M
Diluted EPS (ttm)-1.3600
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)119.11M
Total cash per share (mrq)1.68
Total debt (mrq)3.5M
Total debt/equity (mrq)2.23%
Current ratio (mrq)4.16
Book value per share (mrq)2.22

Cash flow statement

Operating cash flow (ttm)-78.33M
Levered free cash flow (ttm)-39.92M